centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).
DM199-2021-001
Phase 3 small_molecule active
Quick answer
centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API). for Acute Ischemic Stroke is a Phase 3 program (small_molecule) at DiaMedica Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- DiaMedica Therapeutics
- Indication
- Acute Ischemic Stroke
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active